Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL768607 | 0.91 | CHRM3 (0.51) | CHRM3SLC2A1 | |
| SCHEMBL379898 | 0.90 | CHRM3 (0.47) | CHRM3SLC2A1 | |
| SCHEMBL381136 | 0.89 | CHRM3 (0.48) | CHRM3SLC2A1 | |
| SCHEMBL10279589 | 0.89 | CHRM3 (0.51) | CHRM3SLC2A1 | |
| SCHEMBL381592 | 0.87 | CHRM3 (0.51) | CHRM3SLC2A1 | |
| SCHEMBL380326 | 0.87 | CHRM3 (0.64) | CHRM3 | |
| SCHEMBL380992 | 0.84 | CHRM2 (0.60) | CHRM3SLC2A1 | |
| SCHEMBL381053 | 0.84 | CHRM2 (0.60) | CHRM3SLC2A1 | |
| SCHEMBL380424 | 0.84 | CHRM2 (0.50) | CHRM3 | |
| SCHEMBL13174064 | 0.84 | CHRM2 (0.52) | CHRM3SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476253-B2 | Amide derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-07-02 | — | — | US | disclosed |
| US-20120071467-A1 | AMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
| EP-2409977-A1 | AMIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2012-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071467-A1 | AMIDE DERIVATIVE | CHRM3, CHRM2, TACR2 | CHRM3 1/4885SLC2A1 1942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.